Remove DEA Remove Events Remove History
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 105
article thumbnail

From DEA to Legal Cannabis: Charles Feldmann Weighs In

CannaTech

As a Marine Corps federal prosecutor, DEA Drug Task Force Commander and state narcotics prosecutor, Charles spent many years engaged in the War on Drugs. A Former DEA Prosecutor’s Journey into the Global Cannabis Industry. Charles Feldmann, Esq. CannaTech alumnus sponsor and cannabis legal expert. ” – Famous Russian proverb.

DEA 80
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

U.S. Federal Court Tells DEA to Evaluate Rescheduling Cannabis, in Light of its Medical Benefits

WeedAdvisor

In a rather surprising turn of events, a federal appeals court gave marijuana advocates a small opening in their ongoing battle to reschedule marijuana, according to Marijuana Moment. The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA.

DEA 55
article thumbnail

Charles Feldmann to Speak at Canna Tech Global

MJ Business Attorneys

Charles Feldmann, a former DEA Drug Task Force Commander and former state’s narcotics prosecutor, will be sharing his insight and expertise on the other side of the cannabis constitutional law. ” and he will be discussing the following: A brief history of the U.S. Where is it all headed?” policy towards marijuana.

DEA 100
article thumbnail

The Consequences of Not Studying History

Cannabis Law Report

The conference raises numerous questions related to securities laws, the access to capital markets by cannabis industry companies prior to the removal of cannabis from the Controlled Substances Act [“CSA”] by the DEA or Congress, and the level of scrutiny that both public companies and individual investors can expect. FBI Director J.

History 45
article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. This landmark approval is unique in that ketamine is well known to have hallucinogenic properties, as well as a long history as a party drug. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA).

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D.,